INSIGHTS ON DRUG DEVELOPMENT

• Why Early Device Decisions Matter: How Immunovant Accelerated Its Program

  Deferring autoinjector selection can seem to preserve flexibility, yet it often moves constraints downstream. Integrating the device during Phase IIb changed one program's timeline and removed bridging work.

• Moving Faster, With Confidence: Interview With Ulrike Bauer

  What helps programs advance from development to commercial scale? Ulrike Bauer explores the role of platform flexibility, device readiness and tailored support. Watch now.

• Managing Endotoxins - Detect, Prevent, Remove

  Explore the risks of endotoxin contamination in drug manufacturing and discover sustainable, animal-free detection methods to ensure pharmaceutical safety and regulatory compliance.

• Drug Substance For Early Clinical Phase Initiation

  Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.

• New Approaches To Tailored Release Profiles

  7/7/2025

  Tailored drug release is evolving from formulation tactic to precision therapy strategy, optimizing timing, site, and rate of delivery for improved patient outcomes.

• Developing A Quantitative Surrogate Peptide Assay

  7/17/2025

  Discover a streamlined LC-MS/MS workflow for Fc-containing therapeutics like dulaglutide to enable precise quantification with LLOQ as low as 1 ng/mL through automated, efficient assay development.

• How Isogenic Organ-Chips Are Transforming The Future Of Research

  6/25/2026

  Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.

• Futurizing Healthcare By Localizing The Life Sciences

  12/12/2024

  Mustapha Bittaye's journey highlights the importance of international funding in fostering local scientific talent and biopharma resilience, empowering research and manufacturing in developing countries.

• Characterizing Quality Attributes Of GLP-1 Analogs By Light Scattering

  7/31/2025

  Explore how light scattering reveals the structural integrity, aggregation, and stability of GLP-1 analogs to advance drug formulation and enhance treatment efficacy for type 2 diabetes and obesity.